一种优化的机器学习方法,用于预测用于治疗肺高血压的沃戈宁疗法
Yupeng Li1, Yujie Fu2, Yining Liu2
1College of Computer Science and Technology, Changchun Normal University, Changchun, Jilin 130032, China.
这项研究引入了一种新的非侵入性方法,BSCDWOA-KELM,用于预测肺高血压 (PH) 的沃戈宁治疗有效性. 该方法准确地识别了关键的血液指标,为监测PH进展和治疗反应提供了更简单的方法.
科学领域:
- 生物医学工程 生物医学工程
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺高血压 (PH) 对人类健康构成重大风险,导致右心力衰竭.
- 早期发现和监测PH对于有效治疗至关重要.
- 沃贡尼是一种来自Scutellaria baicalensis的化合物,显示出潜在的治疗益处.
研究的目的:
- 在小鼠模型中评估wogonin在缓解PH进展方面的有效性.
- 利用机器学习开发一种新的,非侵入性预测方法,用于在PH中使用Wogonin治疗.
- 为特征选择引入一个增强的鱼优化器 (SCDWOA) 和内核极端学习机器 (KELM).
主要方法:
- 沃贡因对PH的影响在小鼠中使用右心导管和血素-氨酸染色进行了评估.
- 开发了一种新的特征选择方法,BSCDWOA-KELM,结合SCDWOA和KELM,用于非侵入性PH预测.
- 在IEEE CEC2014基准数据集上验证了SCDWOA的优化能力.
主要成果:
- 拟议的SCDWOA在全球优化任务中表现出卓越的融合性能.
- BSCDWOA显著提高了KELM在PH数据集上的分类准确性.
- BSCDWOA-KELM精确选了关键指标 (RBC,HGB,LYM%,HCT,RDW-SD) 的精度超过0.98.
结论:
- BSCDWOA-KELM方法提供了一个准确且非侵入性的方法,用于预测肺高血压中沃贡因治疗.
- 这种计算方法为监测PH进展和治疗反应提供了一个更简单的替代方案.
- 这项研究强调了沃贡宁作为PH治疗剂的潜力.
更多相关视频
08:51Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model
Published on: November 11, 2022
07:15Machine Learning Algorithms for Early Detection of Bone Metastases in an Experimental Rat Model
Published on: August 16, 2020
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
